Surgical Science Sweden AB (publ)
SUSRF News Today: Stay Updated with the Latest Surgical Science Sweden AB (publ) News in Real Time
Find SUSRF news now at Meyka AI. Stay informed with the latest Surgical Science Sweden AB (publ) stocks updates, including price news, market analysis, and expert insights.
Titan Medical Inc. (TMD.TO) Surges 2,150% on Robotic Surgery Momentum
TMD.TO stock explodes 2,150% to C$1.125 on Enos robotic surgery system development. Healthcare innovation drives massive pre-market rally.
Beyond Frames Entertainment Stock Slips 1.9% Ahead of Earnings
8WP.F stock drops 1.9% to €0.207 on XETRA ahead of May 21 earnings announcement. Gaming firm faces profitability challenges.
Intuitive Surgical Stock Edges Higher as Institutional Investors Build Positions
ISRG stock rises 0.38% pre-market as major funds increase holdings. Track Intuitive Surgical’s surgical robotics performance in real-time.
Nanobiotix Stock Tumbles 14% on Clinical-Stage Biotech Headwinds
NANO.PA stock drops 14% to €36.74 as clinical-stage biotech faces profitability challenges and negative cash flow pressures on EURONEXT.
PM Modi Sweden Visit May 20: Honors Deepen India-Europe Ties
PM Modi receives Sweden’s highest honor during Europe visit. Bengali culture celebration and trade focus mark diplomatic milestone on May 20, 2026.
Fameglow Holdings Limited Surges 53.6% on Strong Medical Aesthetic Demand
8603.HK stock jumps 53.6% to HK$8.45 on strong medical aesthetic services demand in Hong Kong market.
Precision System Science Co., Ltd. (7707.T) Surges 16.5% on Strong Earnings Growth
7707.T stock jumps 16.5% to ¥290 on robust earnings growth and operational improvements in medical diagnostics.
Xvivo Perfusion AB (XVIPY) Holds $6.54 as Organ Transplant Tech Faces Valuation Pressure
XVIPY stock trades flat at $6.54 USD. Medical device maker faces elevated valuation metrics and mixed analyst outlook in healthcare sector.
RSSS Lake Street Maintains Buy Rating, May 19 2026
Lake Street maintains Buy rating on RSSS while lowering price target to $4 from $5, citing valuation concerns.